Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153690 (bone metastases)
 6,382 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

On the basis of 110 prostatic osteoses that were histologically proven, constantly painful and demonstrated by X-ray, treated by early estrogenotherapy using very high doses, backed up by a high-dose maintenance estrogenotherapy, the authors study the clinical, radiological, histological and biological profile of this metastatic cancer, as well as the response to treatment. The median actuarial survival time of the patients studied is 18.5 months. No statistically significant prognostic correlation was found. Only patients who are clinically estrogen-sensitive, are suffering from bone metastases without a combined visceral conditions, and have a normal initial rate of alcaline phosphates, tend to have a better prognosis (median actuarial survival 31 months versus 18.5 months for the overall population).
Rev Rhum Mal Osteoartic 1979 Dec
PMID:[Prostatic osteosis. Retrospective study of 110 cases treated with high-dose estrogens]. 11 98

The authors report the results they obtained by bone scintigraphy using technetium pyrophosphate. In a study of 142 patients with cancer, the authors show, as others have done, that bone scintigraphy makes it possible to find bone metastases that are radiologically undetectable and they emphasize the importance of this discovery. In 7 patients with spondylodiscitis, of whom 1 was without radiological signs at the time the scintigraphy was carried out, the authors always observed localized vertebral hyperfixation and they noted that this examination can be valuable for distinguishing spondylodiscitis from pseudo-Pott's discarthroses and from the lesions of vertebral epiphysitis, which in their experience do not result in isotopic hyperfixation. In 7 patients with epiphyseal osteonecrosis, the authors observed isotopic hyperfixation before the appearance of radiological signs. In 12 patients with osteoporosis, the authors observed hyperfixation in bone in certain compressed vertebrae, whereas other vertebrae that had probably been compressed some considerable time earlier did not fix the isotope excessively. They never observed hyperfixation in vertebrae that were not compressed. Among 5 patients with ankylosing spondylitis with radiological signs of sacro-iliac arthritis, the authors observed sacro-iliac hyperfixation in only 3 cases. Two other patients who had signs indicating ankylosing spondylarthritis, but were without radiological signs of sacro-iliac arthritis did not show sacro-iliac hyperfixation of the isotope. Among 7 patients with Paget's disease, the authors observed hyperfixation in all the bones with radiological signs of disease; in addition, in 3 patients, there was also hyperfixation in certain bones that were radiologically clear.
Rev Rhum Mal Osteoartic 1975 Jan
PMID:[Diagnostic value of bone scintigraphy with technetium pyrophosphate. Study of 250 patients]. 16 74

The plasma parathormone was measured by radioimmunological determination in 23 cases of cancer with bone metastases, 8 of mammary origin. In 11 cases the plasma parathormone (iPTH) was less than 4 ng/ml (lower normal limit), as might be expected in view of the hypercalcemia. In 12 cases the iPTH was higher than 4 ng/ml, in 8 of these higher than 8 ng/ml (upper normal limit). These results are suggestive of the role of a substance analogous to parathormone in the genesis of the hypercalcaemia and peritumoral bone resorption of bone metastases of solid tumors.
Rev Rhum Mal Osteoartic 1977 Dec
PMID:[Radioimmunologic determination of plasma parathormone in hypercalcemia caused by cancer with osseous metastases]. 60 75

The first intention imaging modality for detecting bone metastases of non small cell (NSC) bronchogenic carcinoma is bone scintigraphy using technetium-99m pyrophosphate or diphosphonates. This test has a high sensitivity but equivocal images may lead to complementary tests including magnetic resonance imaging (MRI) or bone biopsy. Based on bone metastases prevalence, scintigraphy is recommended for patients entering a therapeutic trial, having bone pain, having a non characteristic bone abnormality on radiography or CT, having a non epidermoid histology or having associated pathologies increasing the risk of surgery. The utility of bone scan is questionable for patients having a Stage I or II epidermoid cancer, having already evidence of bone metastases or for whom the result of the bone scan will not change the therapeutic management. After a negative bone scan, there will be probably an indication for MRI at search of small infra-scintigraphic osteo-medullary metastases.
Rev Mal Respir 1992
PMID:[How can metastatic bone involvement be assessed?]. 133 74

In the presence of prevalent bone metastases, the precise histo-pathological diagnosis of the primary tumor is often difficult. The authors study the diagnostic value of systematic serum assay of a series of tumoral tracers (ACE, AFP, PAP and PSA, SCC, CA 19:9, CA 15:3, CA 125) which until now were used in evolutive and therapeutic monitoring. 34 patients were selected for this preliminary retrospective study (including 20 with a demonstrated histopathological diagnosis). 70 p. cent of prevalent bone metastases express a target tracer corresponding to the initial location. In some cases, an elevated tracer, because of its specificity, may bring about a diagnostic or therapeutic decision (always according to the context). No conclusion may currently be drawn in case of discordance between the anatomo-clinical context and the "profile" of the markers (1 case in our series).
Rev Rhum Mal Osteoartic 1989 Jun
PMID:[Systematic study of various tumoral markers in prevalent bone metastasis]. 275 18

LHRH analogous drugs cause a marked decrease of the testicular secretion, similar to that noted after pulpectomy or estrogen therapy. The experience acquired enables to consider LHRH analogous drugs as alternative in the first intention treatment of the bone metastases prostatic cancer if pulpectomy is refused or if estrogen therapy indicated because of its cardiovascular risks. It is not yet whether the systematic and long-term adjunction of an anti-androgen to LHRH analogous drugs, really increases its efficacy. In the late stage of bone metastases, when the effects of pulpectomy estrogen therapy have ended, LHRH analogous drugs only result in when the tumor process is still hormone-dependent.
Rev Rhum Mal Osteoartic 1988 Nov
PMID:[Importance of analogs of LHRH in the treatment of bone metastasis of cancer of the prostate in 1988]. 306 Sep 74

The three fold interest of bone scintiscanning is discussed in relation to 182 cases of bone metastases of various origins. Firstly, this technic facilitates early diagnosis of invasion of the bone by the detection of metastatic lesions which, in 7.7% of cases are still infraradiologic, or even of reflex algodystrophy of the legs, which can be detected only from a scintiscan, long before X-ray plates can show the lumbar metastasis which is responsible. Secondly, the method is able to pick up more metastatic sites in 54.4% of cases than can be detected by X-ray; this is confirmed by investigation of the S/R ratio (ratio of the number of strongly binding sites to the number of sites showing radiologic damage) which is greater than unity for a considerable period. Thirdly, repeated scintiscanography provides a prognosis, because the survival time appears to be fairly closely correlated with the regression, stability or extension of strongly binding sites, although a "flare phenomenon" may give the erroneous impression that the metastatic process has deteriorated. Repeated scintiscanography also provides a good way of evaluating the efficacy of medical treatment, particularly in the case of bone metastases of mammary or prostatic origin. Sometimes, the decision for or against prophylactic or palliative orthopedic surgery may be based to a considerable extent on data provided by scintiscan.
Rev Rhum Mal Osteoartic 1986 May
PMID:[Bone scintigraphy in metastases]. 373 95

18 French women with bone metastases of breast cancer were treated with norethisterone 60 mg per day (except 1 woman given 20 mg daily) for 2 months or until the end of the remission from 1969-1972. The patients ranged from 39-84 years (mean 57.7). In 16 breast cancer had 0een diagnosed 6 months to 16 years before (mean 43 months). Calcemia was less than 102 mg per 1; calcuria was above 250 mg per 24 hours in 3. The bone lesions were lytic in 13 and mixed in 5. Progestagens were the first treatment for bone metastases in 10; others had ovariectomy, androgens, cortisone, chemotherapy, adrenalectomy, and hypophysectomy. Since the response of these metastases is difficult to evaluate, the authors chose criteria of disappearance of pain and stabilization of radiographic lesions. In 6 patients pain was relieved within 2-4 weeks, and lesions stabilized or recalcified in 2. In 5 of the 6 erythrocyte sedimentation rate became normal in 2 months; calcemia normalized in 1; calcuria decreased in 4. Remission lasted 3-9 months (mean 5.6). After remission, androgens were effective in 3 or 4. In 6, norethisterone was stopped because it was ineffective. 6 others had to stop for intolerance: vomiting in 1, jaundice in 2, hypercalcemia in 3.
Rev Rhum Mal Osteoartic 1974 Jan
PMID:[Treatment of bone metastases of breast cancer with progestogens]. 482 May 23

Bony metastases are a source of numerous complications and remain a difficult therapeutic target. Malignant cells implant in bony tissue where they can secrete factors which stimulate resorption and/or bone formation. The nature of these factors is now being discovered, even though their mode of action is better understood: the osteolytic action of prostaglandin E2 secreted in breast cancer, or the osteogenesis stimulating action of "transforming growth factor" in prostatic cancer. Progress in these areas of research is soon forthcoming due to new techniques in molecular biology.
Rev Rhum Mal Osteoartic 1984 Dec 15
PMID:[Resorption and formation in metastatic bone]. 639 2

We report the case of a 38 year-old man admitted for the treatment of a neuroendocrine carcinoma of the lung with multiple bone metastases. At the diagnosis, the serum biochemistry revealed an evidence of malignant hypercalcemia with acute renal impairment. At this point, a Tc 99-m MDP bone scan was performed and showed intense uptake throughout the gastric walls. The patient underwent a repeat bone scan after normalization of biochemistry; no more abnormal uptake was noted in the stomach. Hypercalcemia is an abnormality of the calcium metabolism frequently associated with malignant condition. Metastatic calcification results from increased accumulation of the calcium-phosphate salts in different tissues related to a local physiological alcalinity. Usually reversible, metastatic calcifications appear as various extraskeletal uptake at Tc 99-m MDP bone scan.
Rev Mal Respir 2001 Dec
PMID:[Metastatic gastric calcifications and bronchial neuroendocrine tumor]. 1192 91


1 2 Next >>